Epstein–Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions

• DOI: 10.1099/jgv.0.000889
• Publication Date: 2017-08-08T14:20:13Z
• Authors: V. E. Gurtsevitch; N. B. Senyuta; A. V. Ignatova; M. V. Lomaya; V. N. Kondratova; A. I. Pavlovskaya; T. E. Dushenkina; D. M. Maximovich; K. V. Smirnova; A. M. Mudunov; A. V. Lichtenstein
• Keywords: Adult; Male; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Nasopharyngeal Carcinoma; Carcinoma; Nasopharyngeal Neoplasms; Middle Aged; Antibodies, Viral; Russia; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; DNA, Viral; Humans; Capsid Proteins; Female

The Epstein–Barr virus (EBV) plays a key role in the development of undifferentiated nasopharyngeal carcinoma (uNPC). In uNPC endemic regions EBV-specific antibodies and plasma EBV DNA load are used as markers for early detection monitoring disease. non-endemic regions, such studies were practically not conducted. aim this study was to compare clinical significance serological levels patients region, Russia. results obtained indicate that both viral capsid antigen/immunoglobulin A (VCA/IgA) copies can effectively be (NPC) diagnosis. Besides, found more sensitive marker than VCA/IgA antibody titres, it reflected effect therapy stages remission relapse disease precisely. Our study, first time, demonstrates simultaneous use loads indispensable regions: NPC screening, but better However, turned out unsuitable assessing status patients. Serological did correlate with any signs tumour process estimated by tumour, node metastasis (TNM) classification correlated only size pathologically altered lymph nodes (N). Additional is required confirm these findings.